Sign up to save your podcasts
Or
Share ONCOLOGY: ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ONCOLOGY: ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up
Audio Journal of Oncology, December 15th, 2007
Reporting from: San Antonio Breast Cancer Symposium, 13-16 December, 2007
ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up
JACK CUZICK, Wolfson Institute of Preventive Medicine, London
REFERENCE: ABSTRACTS 41, 2069, 2071
New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data now show a benefit in the time to distant recurrence. Derek Thorne heard more from Jack Cuzick, of the Wolfson Institute of Preventive Medicine in London.
View all episodes
By Audio MedicaAudio Journal of Oncology, December 15th, 2007
Reporting from: San Antonio Breast Cancer Symposium, 13-16 December, 2007
ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up
JACK CUZICK, Wolfson Institute of Preventive Medicine, London
REFERENCE: ABSTRACTS 41, 2069, 2071
New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data now show a benefit in the time to distant recurrence. Derek Thorne heard more from Jack Cuzick, of the Wolfson Institute of Preventive Medicine in London.